메뉴 건너뛰기




Volumn 87, Issue 3, 2012, Pages 308-310

Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FERRIC GLUCONATE; FERROUS SULFATE; IRON; PLATINUM; RECOMBINANT ERYTHROPOIETIN;

EID: 84857043535     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22262     Document Type: Letter
Times cited : (65)

References (26)
  • 1
    • 0033530262 scopus 로고    scopus 로고
    • Chemotherapy-induced anemia in adults: Incidence and treatment
    • Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
    • (1999) J Natl Cancer Inst , vol.91 , pp. 1616-1634
    • Groopman, J.E.1    Itri, L.M.2
  • 2
    • 20844434968 scopus 로고    scopus 로고
    • Cancer-related anemia: Pathogenesis, prevalence and treatment
    • Birgegård G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: Pathogenesis, prevalence and treatment. Oncology 2005; 68: 3-11.
    • (2005) Oncology , vol.68 , pp. 3-11
    • Birgegård, G.1    Aapro, M.S.2    Bokemeyer, C.3
  • 3
    • 5344263788 scopus 로고    scopus 로고
    • The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
    • Ludwig H, Belle SV, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306.
    • (2004) Eur J Cancer , vol.40 , pp. 2293-2306
    • Ludwig, H.1    Belle, S.V.2    Barrett-Lee, P.3
  • 4
    • 67651146893 scopus 로고    scopus 로고
    • The anemia of inflammation/malignancy: Mechanisms and management
    • Adamson J. The anemia of inflammation/malignancy: Mechanisms and management. Am Soc Hematol Education Prog 2008; 1: 159-165.
    • Am Soc Hematol Education Prog , vol.2008 , Issue.1 , pp. 159-165
    • Adamson, J.1
  • 5
    • 78649753411 scopus 로고    scopus 로고
    • Detection, evaluation, and management of iron-restricted erythropoesis
    • Goodnough L. Detection, evaluation, and management of iron-restricted erythropoesis. Blood 2010; 116: 4754-4761.
    • (2010) Blood , vol.116 , pp. 4754-4761
    • Goodnough, L.1
  • 6
    • 65449117261 scopus 로고    scopus 로고
    • Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials
    • Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
    • (2009) Lancet , vol.373 , pp. 1532-1542
    • Bohlius, J.1    Schmidlin, K.2    Brillant, C.3
  • 7
    • 67649934442 scopus 로고    scopus 로고
    • Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia
    • Ludwig H, Crawford J, Österborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27: 2838-2847.
    • (2009) J Clin Oncol , vol.27 , pp. 2838-2847
    • Ludwig, H.1    Crawford, J.2    Österborg, A.3
  • 8
    • 75549086280 scopus 로고    scopus 로고
    • Erythropoiesis-stimulating agents in oncology: A study level meta analysis of survival and other safety outcomes
    • Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: A study level meta analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-315.
    • (2010) Br J Cancer , vol.102 , pp. 301-315
    • Glaspy, J.1    Crawford, J.2    Vansteenkiste, J.3
  • 9
    • 78751499254 scopus 로고    scopus 로고
    • FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp
    • U.S. Food and Drug Administration
    • U.S. Food and Drug Administration. FDA Drug Safety Communication: Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm#SA.
  • 10
    • 33646905411 scopus 로고    scopus 로고
    • Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
    • Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708-714.
    • (2006) J Natl Cancer Inst , vol.98 , pp. 708-714
    • Bohlius, J.1    Wilson, J.2    Seidenfeld, J.3
  • 11
    • 73349121307 scopus 로고    scopus 로고
    • Anemia management in oncology and hematology
    • Spivak JL, Gascón P, Ludwig H. Anemia management in oncology and hematology. Oncologist 2009; 14: 43-56.
    • (2009) Oncologist , vol.14 , pp. 43-56
    • Spivak, J.L.1    Gascón, P.2    Ludwig, H.3
  • 12
    • 40349103260 scopus 로고    scopus 로고
    • Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
    • Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. J Am Med Assoc 2008; 299: 914-924.
    • (2008) J Am Med Assoc , vol.299 , pp. 914-924
    • Bennett, C.L.1    Silver, S.M.2    Djulbegovic, B.3
  • 13
    • 33646345152 scopus 로고    scopus 로고
    • KDOQI clinical practice guildelines and clinical practice recommendations for anemia in chronic kidney disease
    • Foundation NK. KDOQI clinical practice guildelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S1-S146.
    • (2006) Am J Kidney Dis , vol.47
    • Foundation, N.K.1
  • 14
    • 6344254701 scopus 로고    scopus 로고
    • Iron deficiency and thrombosis: Literature review
    • Keung Y-K, Owen J. Iron deficiency and thrombosis: Literature review. Clin Appl Thrombosis/Hemostasis 2004; 10: 387-391.
    • (2004) Clin Appl Thrombosis/Hemostasis , vol.10 , pp. 387-391
    • Keung, Y.-K.1    Owen, J.2
  • 15
    • 29144486069 scopus 로고    scopus 로고
    • Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
    • Khorana A, Francis C, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104: 2822-2829.
    • (2005) Cancer , vol.104 , pp. 2822-2829
    • Khorana, A.1    Francis, C.2    Culakova, E.3
  • 16
    • 0028596458 scopus 로고
    • Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: Correlation of platelet count with erythropoietic activity and iron parameters
    • Beguin Y, Loo M, R'Zik S, et al. Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: Correlation of platelet count with erythropoietic activity and iron parameters. Eur J Haematol 1994; 53: 265-270.
    • (1994) Eur J Haematol , vol.53 , pp. 265-270
    • Beguin, Y.1    Loo, M.2    R'Zik, S.3
  • 17
    • 44649121569 scopus 로고    scopus 로고
    • Thrombosis with erythropoietic stimulating agents-Does iron-deficient erythropoiesis play a role?
    • Dahl NV, Henry D, Coyne DW. Thrombosis with erythropoietic stimulating agents-Does iron-deficient erythropoiesis play a role? Seminars Dialysis 2008; 21: 210-211.
    • (2008) Seminars Dialysis , vol.21 , pp. 210-211
    • Dahl, N.V.1    Henry, D.2    Coyne, D.W.3
  • 18
    • 33847046008 scopus 로고    scopus 로고
    • Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy
    • Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242.
    • (2007) Oncologist , vol.12 , pp. 231-242
    • Henry, D.H.1    Dahl, N.V.2    Auerbach, M.3
  • 19
    • 43249124234 scopus 로고    scopus 로고
    • Should intravenous iron be the standard of care in oncology?
    • Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008; 26: 1579-1581.
    • (2008) J Clin Oncol , vol.26 , pp. 1579-1581
    • Auerbach, M.1
  • 20
    • 79955031500 scopus 로고    scopus 로고
    • Parenteral iron therapy in cancer-associated anemia
    • Henry D. Parenteral iron therapy in cancer-associated anemia. Hematology 2010; 1: 351-356.
    • Hematology , vol.2010 , Issue.1 , pp. 351-356
    • Henry, D.1
  • 21
    • 79951986687 scopus 로고    scopus 로고
    • Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia
    • Steensma D, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011; 29: 97-105.
    • (2011) J Clin Oncol , vol.29 , pp. 97-105
    • Steensma, D.1    Sloan, J.A.2    Dakhil, S.R.3
  • 22
    • 84857055492 scopus 로고    scopus 로고
    • The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial
    • abstr 9031.
    • Steensma DP, Sasu BJ, Sloan JA, et al. The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. J Clin Oncol 2011; 29( Suppl); abstr 9031.
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL.
    • Steensma, D.P.1    Sasu, B.J.2    Sloan, J.A.3
  • 23
    • 84873075963 scopus 로고    scopus 로고
    • Safety concerns associated with aranesp (Darbepoetin Alfa) Amgen, Inc. and Procrit (Epoetin Alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy.
    • Luksenburg H, Weir A, Wager R. Safety concerns associated with aranesp (Darbepoetin Alfa) Amgen, Inc. and Procrit (Epoetin Alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2_04_fda-aranesp-procrit.htm.
    • Luksenburg, H.1    Weir, A.2    Wager, R.3
  • 24
    • 79955024469 scopus 로고    scopus 로고
    • Iron supplementation to treat anemia in patients with chronic kidney disease
    • Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol 2010; 6: 699-710.
    • (2010) Nat Rev Nephrol , vol.6 , pp. 699-710
    • Besarab, A.1    Coyne, D.W.2
  • 25
    • 33947212276 scopus 로고    scopus 로고
    • Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study
    • Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007; 18: 975-984.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 975-984
    • Coyne, D.W.1    Kapoian, T.2    Suki, W.3
  • 26
    • 69549104049 scopus 로고    scopus 로고
    • Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy
    • Kuderer N, Khorana A, Francis C. Venous thromboembolism risk model predicts early progression and overall mortality in cancer patients receiving chemotherapy. Blood 2008; 112: 172.
    • (2008) Blood , vol.112 , pp. 172
    • Kuderer, N.1    Khorana, A.2    Francis, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.